Estrogen and MYB in breast cancer:: potential for new therapies

被引：33
作者：
Gonda, Thomas J. [1 ]
Leo, Paul [1 ]
Ramsay, Robert G. [2 ]
机构：
[1] Univ Queensland Diamantina, Inst Canc Immunol & Metab Med, Brisbane, Qld, Australia
[2] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2008年 / 8卷 / 06期
基金：
英国医学研究理事会;
关键词：
breast cancer; estrogen; MYB;
D O I：
10.1517/14712598.8.6.713
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
MYB is highly expressed in almost all estrogen receptor (ER)-positive breast tumours and is a direct target of estrogen/ER signalling. Our recent studies have shown that MYB is also required for the proliferation of ER-positive breast tumour cell lines, and have shed further light on the mechanism of ER regulation of MYB expression. Here we discuss the rationale for therapeutic targeting of MYB in breast cancer and consider a number of approaches to developing an anti-MYB therapeutic.
引用
收藏
页码：713 / 717
页数：5
相关论文
共 22 条
  • [1] DIFFERENTIAL EXPRESSION OF C-MYB MESSENGER-RNA IN MURINE-B LYMPHOMAS BY A BLOCK TO TRANSCRIPTION ELONGATION
    BENDER, TP
    THOMPSON, CB
    KUEHL, WM
    [J]. SCIENCE, 1987, 237 (4821) : 1473 - 1476
  • [2] c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer -: Clinical and experimental findings
    Biroccio, A
    Benassi, B
    D'Agnano, I
    D'Angelo, C
    Buglioni, S
    Mottolese, M
    Ricciotti, A
    Citro, G
    Cosimelli, M
    Ramsay, RG
    Calabretta, B
    Zupi, G
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (04) : 1289 - 1299
  • [3] NORMAL AND LEUKEMIC HEMATOPOIETIC-CELLS MANIFEST DIFFERENTIAL SENSITIVITY TO INHIBITORY EFFECTS OF C-MYB ANTISENSE OLIGODEOXYNUCLEOTIDES - AN INVITRO STUDY RELEVANT TO BONE-MARROW PURGING
    CALABRETTA, B
    SIMS, RB
    VALTIERI, M
    CARACCIOLO, D
    SZCZYLIK, C
    VENTURELLI, D
    RATAJCZAK, M
    BERAN, M
    GEWIRTZ, AM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (06) : 2351 - 2355
  • [4] Interfering with disease: a progress report on siRNA-based therapeutics
    de Fougerolles, Antonin
    Vornlocher, Hans-Peter
    Maraganore, John
    Lieberman, Judy
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (06) : 443 - 453
  • [5] Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells
    Drabsch, Yvette
    Hugo, Honor
    Zhang, Rui
    Dowhan, Dennis H.
    Miao, Yu Rebecca
    Gewirtz, Alan M.
    Barry, Simon C.
    Ramsay, Robert G.
    Gonda, Thomas J.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (34) : 13762 - 13767
  • [6] Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype
    Frasor, J
    Danes, JM
    Komm, B
    Chang, KCN
    Lyttle, CR
    Katzenellenbogen, BS
    [J]. ENDOCRINOLOGY, 2003, 144 (10) : 4562 - 4574
  • [7] Myb and oncogenesis
    Ganter, B
    Lipsick, JS
    [J]. ADVANCES IN CANCER RESEARCH, VOL 76, 1999, 76 : 21 - 60
  • [8] Cellular control of gene expression by T-type cyclin/CDK9 complexes
    Garriga, J
    Graña, X
    [J]. GENE, 2004, 337 : 15 - 23
  • [9] GUERIN M, 1990, ONCOGENE, V5, P131
  • [10] Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Hess, Kenneth R.
    Anderson, Keith
    Symmans, W. Fraser
    Valero, Vicente
    Ibrahim, Nuhad
    Mejia, Jaime A.
    Booser, Daniel
    Theriault, Richard L.
    Buzdar, Aman U.
    Dempsey, Peter J.
    Rouzier, Roman
    Sneige, Nour
    Ross, Jeffrey S.
    Vidaurre, Tatiana
    Gomez, Henry L.
    Hortobagyi, Gabriel N.
    Pusztai, Lajos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) : 4236 - 4244
123